quizartinib dihydrochloride

{
  "id": "MLC-T-ONC-007129",
  "term": "quizartinib dihydrochloride",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with certain chemotherapy drugs and then alone as maintenance therapy to treat adults with newly diagnosed acute myeloid leukemia that has a certain mutation in the FLT3 gene. It is also being studied in the treatment of other types of cancer. Quizartinib dihydrochloride blocks FLT3 and other proteins, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called Vanflyta.",
    "The dihydrochloride salt form of quizartinib, an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases."
  ],
  "synonyms": [
    "Vanflyta",
    "N-(5-tert-butyl-isoxazol-3-yl)-N'-(4-(7-(2-morpholin-4-ylethoxy)imidazo(2,1-b)(1,3)benzothiazol-2-yl)phenyl)urea dihydrochloride",
    "AC010220 2HCl"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/quizartinib-dihydrochloride/"
}